17753 Analysis of 24-week response to ruxolitinib cream for the treatment of vitiligo based on patient demographics and clinical characteristics

Abstract

Ruxolitinib cream, a Janus kinase inhibitor, is under investigation for vitiligo treatment. Factors including skin type and disease duration may contribute to treatment efficacy. This 24-week component of a 104-week, phase 2, randomized, double-blind study (NCT03099304) enrolled adult patients with vitiligo that included depigmentation ≥0.5% of body surface area (BSA) on the face and ≥3% of BSA on nonfacial areas. 157 patients were equally randomized to receive ruxolitinib cream (1.5% twice daily [bid], 1.5% once daily [QD], 0.5% QD, or 0.15% QD) or vehicle bid for 24 weeks.